CoVaRR-Net Funded Research Results

CoVaRR-Net Funded Research Results2025-03-31T12:52:07-04:00

CoVaRR-Net Funded Publications

CoVaRR-Net was extremely productive with regards to scientific outputs relative to the research funding invest­ments it received. In its four years of operation, the Network’s members produced 139 peer-reviewed research publications, 12 preprints and 15 other types of publications, including live systematic reviews and public health recommendations.

In an effort to make the science more understandable to a wider audience, CoVaRR-Net wrote lay summaries of many of its funded publications, listed below.

The RNA interference effector protein Argonaute 2 functions as a restriction factor against SARS-CoV-2

May 23, 2024|Funded Research Results, Pillar 4|

Plants, insects, and invertebrates defend against virus infections by using an RNA based system, called RNA interference or RNAi. RNAi uses small pieces of the viral genome, termed small interfering RNAs (siRNAs) to target and destroy infectious viral genomes by using a protein that cleaves RNA, called Argonaute.

Estimating SARS-CoV-2 seroprevalence in Canadian blood donors, April 2020 to March 2021: improving accuracy with multiple assays

May 22, 2024|Funded Research Results, Pillar 4|

Seroprevalence data can provide key insights about incidence of infection and exposure to pathogens during epidemics. Serological studies have affirmed that an antibody response is correlated with clearance of viral shedding, have helped confirm true infections, and have helped identify populations with elevated risks of infection.

Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients

May 22, 2024|Funded Research Results, Pillar 4|

Neutralizing antibodies are generated in response to vaccination and infection and their function is to block entry of a pathogen into host cells. The Omicron variants of SARS-CoV-2 contain mutations in the spike protein sequence that can escape recognition by neutralizing antibodies, which can allow the SARS-CoV-2 viral variant to evade immunity.

Go to Top